Cargando…

Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor

Production of bioactive peptides (BAPs) by Lactobacillus species is a cost-effective approach compared to the use of purified enzymes. In this study, proteolytic Lactobacillus helveticus strains were used for milk fermentation to produce BAPs capable of inhibiting angiotensin converting enzyme (ACE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Raveschot, Cyril, Deracinois, Barbara, Bertrand, Emmeline, Flahaut, Christophe, Frémont, Marc, Drider, Djamel, Dhulster, Pascal, Cudennec, Benoit, Coutte, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546403/
https://www.ncbi.nlm.nih.gov/pubmed/33102467
http://dx.doi.org/10.3389/fbioe.2020.585815
_version_ 1783592224076857344
author Raveschot, Cyril
Deracinois, Barbara
Bertrand, Emmeline
Flahaut, Christophe
Frémont, Marc
Drider, Djamel
Dhulster, Pascal
Cudennec, Benoit
Coutte, François
author_facet Raveschot, Cyril
Deracinois, Barbara
Bertrand, Emmeline
Flahaut, Christophe
Frémont, Marc
Drider, Djamel
Dhulster, Pascal
Cudennec, Benoit
Coutte, François
author_sort Raveschot, Cyril
collection PubMed
description Production of bioactive peptides (BAPs) by Lactobacillus species is a cost-effective approach compared to the use of purified enzymes. In this study, proteolytic Lactobacillus helveticus strains were used for milk fermentation to produce BAPs capable of inhibiting angiotensin converting enzyme (ACE). Fermented milks were produced in bioreactors using batch mode, and the resulting products showed significant ACE-inhibitory activities. However, the benefits of fermentation in terms of peptide composition and ACE-inhibitory activity were noticeably reduced when the samples (fermented milks and non-fermented controls) were subject to simulated gastrointestinal digestion (GID). Introducing an ultrafiltration step after fermentation allowed to prevent this effect of GID and restored the effect of fermentation. Furthermore, an integrated continuous process for peptide production was developed which led to a 3 fold increased peptide productivity compared to batch production. Using a membrane bioreactor allowed to generate and purify in a single step, an active ingredient for ACE inhibition.
format Online
Article
Text
id pubmed-7546403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75464032020-10-22 Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor Raveschot, Cyril Deracinois, Barbara Bertrand, Emmeline Flahaut, Christophe Frémont, Marc Drider, Djamel Dhulster, Pascal Cudennec, Benoit Coutte, François Front Bioeng Biotechnol Bioengineering and Biotechnology Production of bioactive peptides (BAPs) by Lactobacillus species is a cost-effective approach compared to the use of purified enzymes. In this study, proteolytic Lactobacillus helveticus strains were used for milk fermentation to produce BAPs capable of inhibiting angiotensin converting enzyme (ACE). Fermented milks were produced in bioreactors using batch mode, and the resulting products showed significant ACE-inhibitory activities. However, the benefits of fermentation in terms of peptide composition and ACE-inhibitory activity were noticeably reduced when the samples (fermented milks and non-fermented controls) were subject to simulated gastrointestinal digestion (GID). Introducing an ultrafiltration step after fermentation allowed to prevent this effect of GID and restored the effect of fermentation. Furthermore, an integrated continuous process for peptide production was developed which led to a 3 fold increased peptide productivity compared to batch production. Using a membrane bioreactor allowed to generate and purify in a single step, an active ingredient for ACE inhibition. Frontiers Media S.A. 2020-09-25 /pmc/articles/PMC7546403/ /pubmed/33102467 http://dx.doi.org/10.3389/fbioe.2020.585815 Text en Copyright © 2020 Raveschot, Deracinois, Bertrand, Flahaut, Frémont, Drider, Dhulster, Cudennec and Coutte. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Raveschot, Cyril
Deracinois, Barbara
Bertrand, Emmeline
Flahaut, Christophe
Frémont, Marc
Drider, Djamel
Dhulster, Pascal
Cudennec, Benoit
Coutte, François
Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title_full Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title_fullStr Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title_full_unstemmed Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title_short Integrated Continuous Bioprocess Development for ACE-Inhibitory Peptide Production by Lactobacillus helveticus Strains in Membrane Bioreactor
title_sort integrated continuous bioprocess development for ace-inhibitory peptide production by lactobacillus helveticus strains in membrane bioreactor
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546403/
https://www.ncbi.nlm.nih.gov/pubmed/33102467
http://dx.doi.org/10.3389/fbioe.2020.585815
work_keys_str_mv AT raveschotcyril integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT deracinoisbarbara integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT bertrandemmeline integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT flahautchristophe integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT fremontmarc integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT driderdjamel integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT dhulsterpascal integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT cudennecbenoit integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor
AT couttefrancois integratedcontinuousbioprocessdevelopmentforaceinhibitorypeptideproductionbylactobacillushelveticusstrainsinmembranebioreactor